Current opinion: Safety evaluation of drug metabolites in development of pharmaceuticals

Journal of Toxicological Sciences

Volumn 32, Issue 4, 2007, Pages 329-341

  Naito, Shinsaku ^a   Furuta, Shigeru ^a   Yoshida, Takemi ^b   Kitada, Mitsukazu ^c   Fueki, Osamu ^d   Unno, Takashi ^e   Ohno, Yasuo ^f   Onodera, Hiroshi ^d   Kawamura, Nobuyuki ^g   Kurokawa, Misao ^a   Sagami, Fumio ^a   Shinoda, Kazutoshi ^d   Nakazawa, Takahiro ^a   Yamazaki, Tsuneyoshi ^h  

^a Torii Nihonbashi Building   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

^d PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^e 4F Landic II   (Japan)

^f NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^g Development and Medical Affairs Division   (Japan)

^h KEIO UNIVERSITY   (Japan)

Author keywords

Active metabolites; Clinical study; Drug development; Metabolites; Non clinical study; Reactive metabolites; Safety

Indexed keywords

ACROLEIN; AFLATOXIN; ALCOHOL; ALPIDEM; ANILINE; BENOXAPROFEN; BENZENE; BROMOBENZENE; CHLOROFORM; CISPLATIN; DACARBAZINE; DANTROLENE; DICLOFENAC; DIETHYLSTILBESTROL; DRUG METABOLITE; FLUOROURACIL; HEXAMETHONIUM; IPRONIAZID; NEFAZODONE; NORPHENAZONE; ORGANOPHOSPHATE INSECTICIDE; PARACETAMOL; PIOGLITAZONE; QUETIAPINE; SORIVUDINE; THIOACETAMIDE; TIENILIC ACID; TROGLITAZONE; UNINDEXED DRUG; ZOMEPIRAC;

CARCINOGENESIS; CARCINOGENICITY; CLINICAL RESEARCH; DRUG ANTAGONISM; DRUG DETOXIFICATION; DRUG FATALITY; DRUG METABOLISM; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HUMAN; LIVER INJURY; LIVER TOXICITY; MUTAGENICITY; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

EID: 35648982920     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.329     Document Type: Review

References (23)

1. Baillie, T.A., Cayen, M.N., Fouda, H., Gerson, R.J., Green, J.D., Grossman, S.J., Klunk, L.J., LeBlanc, B., Perkins, D.G. and Shipley, L.A. (2002): Drug metabolites in safety testing. Toxicol. Appl. Pharmacol., 182, 188-196.
2. Baillie, T.A., Cayen, M.N., Fouda, H., Gerson, R.J., Green, J.D., Grossman, S.J., Klunk, L.J., LeBlanc, B., Perkins, D.G. and Shipley, L.A. (2003): Reply. Toxicol. Appl. Pharmacol., 190, 93-94.
3. CPMP/EWP/560/95, 17, December (1997): The note of guidance on investigation of drug interactions, Committee for Proprietary Medicinal Products.
4. Davis-Bruno, K. L. and Atrakchi, A. (2006): A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol., 19, 1561-1563.
5. FDA CDER Guidance for Industry, Published in Federal Register, March (2003): Guidance for Industry; Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations.
6. FDA CDER Guidance for Industry, Published in Federal Register, June (2005): Guidance for Industry, Safety Testing of Drug Metabolites (Draft).
7. FDA CDER Guidance for Industry, Published in Federal Register, September (2006): Guidance for Industry; Drug Interaction Studies ? Study Design, Data Analysis, and Implications for Dosing and Labeling (Draft).
8. Guengerich, F.P. (2006): Safety Assessment of Stable Drug Metabolites. Chem. Res. Toxicol., 19, 1559-1560.
9. Hastings, K.L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D. and Osterberg, R.E. (2003): Letter to the Editor. Toxicol. Appl. Pharmacol., 190, 91-92.
10. Humphreys, W.G. and Unger, S.E. (2006): Safety assessment of drug metabolites: Characterization of chemically stable metabolites. Chem. Res. Toxicol., 19, 1564-1569.
11. Inoue, T., Harada, Y., Furuta, S., Kawamura, Y., Kurihara, A., Kurokawa, M., Nakazawa, T. and Sagami, F. (2005): The industry's concerns on the inquiries derived from the review of nonclinical studies - Analysis of questionnaire survey data by JPMA, Pharm. Regul. Sci, 36, 388-397.
12. Iyakushin no. 496, Jun. 26th, 1998: Guidance for non-clinical Pharmacokinetic studies.
13. Lazarou, J., Pomeranz, B.H. and Corey, P.N. (1998): Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA., 15, 279, 1200-1205.
14. Ohno, Y. (1992): Toxicity testing: Regulatory Perspectives. Proceedings of the First International Conference on Harmonisation. 1991 Nov.; Brussels, Belgium. Ed D'Arcy PFD and Harron DWG. The Queen's University of Belfast. 186-188.
15. Prueksaritanont, T., Lin, J.H. and Baillie, T.A. (2006): Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol., 217, 143-152.
16. Smith, D.A. and Obach, R.S. (2005): Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos., 33, 1409-1417.
17. Smith, D.A. and Obach, R.S. (2006): Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol., Dec., 19, 1570-1579.
18. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T. and Kamataki, T. (1996): Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56, 3752-3757.
19. The Japanese Society for the Study of Xenobiotics (JSSX, November 29th - December 1st, 2006, Tokyo): 21st Annual Meeting Abstracts 171-177.
20. The Pharmaceutical Society of Japan (Jan. 13th, 2007, Tokyo): Kick-Off Meeting of Drug Evaluation Forum - Toward an Innovative Medicine: From Non-clinical to Clinical. Abstracts.
21. Toxicology Q&A (2003): (Question 16 : Toxicological evaluation of unique human metabolites), Pharm. Regul. Sci, 34, 794-795.
22. Yakushin no. 526, March 28th, 1975: Points to Consider for Approval Application Data for New Manufacture or Import Drugs.
23. Yamada, H., Yamaguchi, J., Iida, I. and Okuyama, S. (2006): Idiosyncratic drug toxicity, Folia Pharmacol. Jpn., 127, 473-480.